Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC)

Table 2

Comparison of the clinical intervention effects of the two groups after the intervention of the included patients.

Group	Basically improved	Partial improvement	Stable condition	Disease progression	Total intervention effectiveness
Treatment group A ()	13 (30.95)	11 (26.19)	10 (23.81)	8 (19.05)	24 (57.14)
Treatment group B ()	24 (54.54)	13 (29.54)	5 (11.36)	2 (4.54)	37 (84.09)
	—				7.678
	—				<0.05